Latest Breaking News On - Division of arthritis rheumatic diseases - Page 1 : vimarsana.com

Results revealed a consistent safety profile with low rates of discontinuation and no increase in adverse events with prolonged treatment exposure in patients treated with ixekizumab.

United statesOregon health science universityDivision of arthritis rheumatic diseasesArthritis researchAtul deodharRheumatic diseasesOregon healthScience university